Two types of maoi out there: covalent and reversible maois. Covalent maois (phenelzine, trancypromine, selegiline) get metabolized by monoamine oxidase and converted to highly reactive species that bond with the enzyme and inhibit it. Reversible inhibitors of monoamine oxidase a (rimas) (such as moclobemide, harmaline, harmine) simply bind to the active site and resist metabolism, displaying on and off kinetics like any non covalent ligand binding to a receptor.
The reason that irreversible maois cause cheese syndrome is that chronic steady state dosing of them induces pretty much complete inactivation of the pool of monoamine oxidases that they target. Thus the body is unable to break down large doses of tyramine.
With rimas there will be an equilibrium of both drug-bound and drug-unbound monoamine oxidase a, so some amount of tyramine (or anything else) will be still getting metabolized.
I would be wary of combining even rimas with any serotonin releaser. That is just asking for trouble. With maois you get the double issue of inhibiting both the parent drug's metabolism and the metabolism of serotonin, which really decreases the margins of a good recreational dose to an overdose.